1 / 29

Pneumonia

Pneumonia. Yong Lee ICU Registrar John Hunter Hospital. Objectives . Pathogenesis Pathophysiology Clinical features Community acquired pneumonia, investigations, assessments of severity, empirical therapy MRSA Influenza Nosocomial pneumonia . Pathogenesis. 3 major routes of entry

kirby
Download Presentation

Pneumonia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pneumonia Yong Lee ICU Registrar John Hunter Hospital

  2. Objectives • Pathogenesis • Pathophysiology • Clinical features • Community acquired pneumonia, investigations, assessments of severity, empirical therapy • MRSA Influenza • Nosocomial pneumonia

  3. Pathogenesis • 3 major routes of entry • Oropharyngeal or gastric aspiration * • Inhalation of aerosols • Haematogenous • Upper airway colonisation • S.Pneumoniae, H. Influenzae, Mixed aerobic and anaerobic bacteria • E.Coli, Klebsiella more frequent in alcoholics, institutionalised elderly, poor oral hygiene • Normal host defenses • Bronchial mucociliary clearance, phagocytic cells in alveoli and bronchial mucosa

  4. Quantity of material aspirated • Uncontrolled seizures, abnormal airway motor control periodontal disease, bronchial obstruction • Nature of bacteria in aspirated material • Highly efficient pathogens (legionella, mycoplasma, chlamydia, coxiella, fungal) • Efficiency of host’s pulmonary defense mechanisms • Post viral respiratory infection, alcoholics, COPD with impaired mucociliary clearance, relative immunologic impairment • Haematogenous spread • Established infection elsewhere (IV drug user) • From damaged skin (brucellosis, melioidosis)

  5. Pathophysiology • Proliferation of microorganisms within pulmonary parenchyma elicit host’s acute inflammatory response • Exudation of protein rich fluid and phagocytic cells • Local mechanical consequences • Impaired distribution of ventilation, decrease in lung compliance -> dyspnoea • V/Q mismatch • Systemic changes • Activation of acute inflammatory response (interleukin 1, cytokines) result in fever, leukocytosis • Bacteremia or microbial antigenemia may activate systemic inflammatory response leading to septic shock

  6. Clinical features • Systemic response • Fever, increased WCC, other sepsis syndromes • Pulmonary symptoms • Cough, sputum production, dyspnoea, pleuritic chest pain • Physical • Inflammatory pulmonary parenchymal process (rales, tachypnoea) • Consolidation (bronchial breathing, dullness to percussion • Abnormal lung function (arterial hypoxaemia, hypocapnia) • Radiographic pulmonary infiltrate c/w pneumonia

  7. Community Acquired Pneumonia

  8. Assessment • Clinical features c/w pneumonia • Consider patient’s age and co-morbidities • The presence of clinical features of organ system failures • CXR demonstrating consolidation • Consider mild (outpatient with appropriate follow up), moderate or severe • Investigation for causal pathogen • Sputum gram stain*, blood cultures • Pneumococcal and legionella urinary antigen assay, nose and throat swab for respiratory viral nucleic acid testing (PCR) • MycoplasmaIgM serology, acute and convalescent serology for mycoplasma, legionella, chlamydophilia and influenza • Procalcitonin* • *BAL

  9. Assessment of severity • PSI (Pneumonia Severity Index) • CURB 65 (Confusion, Urea, Resp rate, Blood pressure, age <65) • Both developed from statistical analyses of features c/w 30 mortality • However majority of patients who die of CAP are elderly persons with multiple co-morbidity • Tools predicting mortality are less accurate in identifying patients who will benefit from admission to ICU • CORB • SMART-COP

  10. CORB C = acute confusion O = oxygen saturation 90% or less R = respiratory rate 30 breaths or more per minute B = systolic blood pressure less than 90 mm Hg or diastolic blood pressure 60 mm Hg or less Interpretation of CORB score • 'Severe CAP' = the presence of at least two of these features. • In the Australian study cohort, the accuracy of CORB for predicting need for IRVS using presence of at least two features was: • sensitivity = 81%, specificity = 68% • positive predictive value (PPV) = 18% • negative predictive value (NPV) = 98% • area under the receiver operating characteristic (ROC) curve = 0.74.

  11. SMART-COP

  12. SMART-COP Interpretation of SMART-COP score • 0 to 2 points—low risk of needing intensive respiratory or vasopressor support (IRVS) • 3 to 4 points—moderate risk (1 in 8) of needing IRVS • 5 to 6 points—high risk (1 in 3) of needing IRVS • 7 or more points—very high risk (2 in 3) of needing IRVS Severe CAP = a SMART-COP score of 5 or more points. • In the Australian Community-Acquired Pneumonia Study (ACAPS) cohort, the accuracy for predicting receipt of IRVS with a SMART-COP score of 3 or more points was: • sensitivity = 92% • specificity = 62% • PPV = 22% • NPV = 99% • area under ROC curve = 0.87. The SMART-COP severity scoring tool can be modified to make it suitable for use by primary care physicians A modified version has also been developed for use in tropical Australia

  13. Empirical management • Mild CAP • Reasonable for single shot benzylpenicillin 1.2g • Amoxycillin 5 – 7 days • Or if atypical is suspected • Doxycycline or Clarithromycin (as single agents) • If no improvement in 48 hrs • Consider dual therapy of amoxycillin + doxycycline or clarithromycin • Some resistant strains of doxycycline and clarithromycin streptococcus pneumoniae in some regions, consider switching to cefuroxime or moxifloxacin or assess need for hospital admission

  14. Empirical management • Moderate CAP • Tropical or non tropical region, risk factors for Burholderiapseudomallei, Acinetobacterbaumannei (DM, chronic lung disease, heavy ETOH, chronic renal failure) • Non tropical, no risk factors • Benzylpenicillin IV PLUS Doxycycline/ Clarithromycin Oral • Add Gentamicin or change to ceftrixone if GN Bacilli identified • Tropical, risk factors • Ceftriaxone PLUS initial dose of Gentamicin

  15. Empirical management • Severe Pneumonia • Non tropical region • Ceftriaxone IV • Benzylpenicillin IV + Gentamicin*(short term empirical or directed therapy only) • Cefotaxime IV • PLUS Azithromycin IV in all cases • Tropical region • Meropenem IV or Imipenem IV • PLUS Azithromycin IV in call cases

  16. Staphylococcal pneumonia • Clinical presentation is suggestive of staphylococcal pneumonia • R sided endocarditis, IVDU, gram stain positive cluster, CXR with cavitatory pneumonia • cMRSA (different from hMRSA) • Increasing esp. in indigenous and pacific islander, IVDU • More clinically aggressive but may be susceptible to routine Abx (clindamycin and bactrim) • Appropriate susceptibility testing is therefore crucial • Hospitalised patients • Intubated patients and late-onset nosocomial infections • Severely ill patients should be treated for BOTH non-MRSA and MRSA (e.gflucloxacillin & Vancomycin) until susceptibility results available

  17. Non MRSA • Flucloxacillin IV • Cephalothin or cephazolin IV (if penicillin hypersensitive) • Vancomycin (if immediate penicillin hypersensitive) • MRSA • Vancomycin IV • *Linezolid, if VISA or hVISA • Consider additional if severe (clindamycin, linezolid, rifampicin + fusidic acid) depending on susceptibility

  18. Influenza • Influenza A and B viruses • Usually cause seasonal minor or major epidemics • Novel strains (e.g H5N1, H1N1) also with potential to cause epidemics due to lack of pre-existing immuniity in humans • Infection is spread by droplets and fomite contact so appropriate infection control are important • Rapid specific testing such as nucleic acid tests (eg polymerase chain reaction [PCR]) for influenza on nose or throat swab specimens are the most useful tests to make the diagnosis • Clinical features alone may be reliable enough for diagnosis when the pre-test probability of influenza is high, for example during known epidemics.

  19. Treatment • Treatment with a neuraminidase inhibitor (oseltamivir or zanamivir) has been associated with a reduced rate of complications of influenza in observational studies • Observational studies have also shown an increase in mortality if hospitalised patients retrospectively shown to have had influenza were not treated with oseltamivir. • Treatment is generally thought to be of greatest benefit if commenced early (ideally within 48 hours of symptom onset), and if targeted to people at highest risk of complications. • Where severe illness (egpneumonitis) is already present, treatment should be offered regardless of the patient's risk group or duration of symptoms • Treatment should be prioritised for people with risk factors for poor outcomes. For these people treatment may be considered even if commenced more than 48 hours after the onset of symptoms.

  20. Treatment • High risk groups • Pregnant women, morbidly obese, underlying chronic disease, immunosuppressed, homeless, nursing home residents, indigenous Australians, the elderly and very young • If treatment indicated • Oseltamivir oral for 5 days OR • Zanamivir inhalation for 5 days • Antibacterials if clinical presentation suggests bacterial or secondary bacterial infection develops • Vaccination with current influenza vaccine provides protection and complications in ~70% of those vaccinated • Recommended for all health care worker, age >65, Aboriginal/ TSI > 15y • Prophylaxis should be considered for close contacts of proven cases, particularly if those contacts are themselves in high-risk groups

  21. Nocosomial Pneumonia or Hospital Acquired Pneumonia HAP • Presentation often unusual because it is affected by advanced age, co-morbidity and neurological disorders • Classic respiratory symptoms often mild and extrapulmonary manifestations (e.g. GI disorder, confusion) are frequeny • Pneumonia that is not incubating at time of admission to hospital and develops in patients hospitalised for 48 h or longer • VAP is usually defined as pneumonia developing ≥48 h after implementing ET intubation and/or mechanical ventilation that was not present before intubation • Divided to early or late onset

  22. Early onset HAP • Within 4 -5 days of hospital admission and tends to be caused by antibiotic sensitive community acquired pathogens • However, increasing frequency of early onset HAP caused by nosocomial pathogens (? Related to concept of healthcare – associated pneumonia) • HCAP - any patient admitted to an acute care hospital for 2 or more days within 90 days of the infection; nursing home resident; attended a hospital or haemodialysis clinic; received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection • Late onset HAP • Tends to be caused by antibiotic resistant hospital opportunists (e.g. Pseudomonas, MRSA)

  23. Diagnosis of HAP • Reliable diagnosis is hard • If one or more of the following criteria are present, pneumonia should be considered in the differential diagnosis: • purulent sputum or tracheal secretions, and new and/or persistent infiltrate on chest X-ray, which is otherwise unexplained • increased oxygen requirement • temperature greater than 38.3 ºC • blood leucocytosis (greater than 11 x 109/L) or leucopenia (less than 4 x 109/L) • The presence of bacteria in expectorated sputum or ETT aspirate usually represent colonisation only, and on its own does not justify a diagnosis of HAP

  24. HAP aetiology • Hospitalised patients frequently develop colonisation of the oropharynx with aerobic GN bacilli, and may also be exposed to multiresistant hospital pathogens e.g.(MRSA), drug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter species and Stenotrophomonasmaltophilia • Recent antibiotic therapy is a distinct risk factor for HAP due to drug-resistant bacteria and/or Pseudomonas aeruginosa • In cases admitted to intensive care for pneumonia management, also consider testing for Legionella (in adults) and influenza infection.

  25. HAP Treatment • Treatment stratification • Low risk of MDR (Low risk ward, high risk area of < 5 days) • High risk of MDR (High risk ward >5 days, consider HCAP) • Antibiotic susceptibility will differ between institutions • Recommended initial antibiotic regimen may need to cover local pathogens and take account of the patient’s recent Abx exposure and culture results • Failure to control infection should prompt re-evaluation of antibiotic therapy and consideration of non-infectious diagnoses

  26. Low risk MDRO • Mild disease • Amoxycillin with clavulanic acid oral OR • Benzylpenicillin + single dose gentamicin • Moderate to severe disease • Ceftriaxone IV OR • Benzylpenicillin + Gentamicin OR • Cefotaxime IV • Tazocin IV • Timentin IV • Antibiotic susceptibility to guide ongoing therapy • Switch to oral Abx after significant improvement • Consider early cessation of therapy in patients who are shown to have alternative diagnosis

  27. High risk MDR organism • Little evidence • Tazocin IV or Timentin IV or Cefepime IV • If ventilated patient, add Gentamicin for 1 dose and determine subsequent 1 or 2 doses dependant of renal function • If predominant GPC (clusters) on gram stain or known to be colonised • Vancomycin IV • Consider risk factors and extrapulmonary symptoms consider Legionella’s • There is evidence that the response to appropriate ABx Rx for ventilated patients occurs within the first 6 days and that prolonged therapy results in colonisation and re-infection with resistant organisms. Treatment for 8 days is recommended except for Pseudomonas aeruginosa or Acinetobacter species when treatment may be needed for up to 15 days.

  28. References • Principles of Critical Care 3rd ed. - J. Hall, G. Schmidt, L. Wood (eds) (Mc-Graw-Hill, 2005) • Therapeutic guidelines, Antibiotics, 2010 • Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas 2007;19(5):418-26 • Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47(3):375-84 • Davis JS, Cross GB, Charles PG, Currie BJ, Anstey NM, Cheng AC. Pneumonia risk stratification in tropical Australia: does the SMART-COP score apply? Med J Aust;192(3):133-6 • Charles PGP, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, et al, the ACAPS Collaboration, Grayson ML. The eitiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46:1513-21

More Related